Unicycive Therapeutics (UNCY)

• Market cap: $60.4M
• 1 day: -1.31%
• 5 days: 5.67%
• 1 month: 3.87%
• 3 months: -18.59%
• 6 months: 47.27%
• Year to date: -26.59%
• 1 year: -58.15%
• 5 years: -90.06%
• 10 years: -90.06%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

157% more capital invested

Capital invested by funds: $19.1M [Q3] → $49M (+$29.9M) [Q4]

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

9.85% more ownership

Funds ownership: 49.58% [Q3] → 59.43% (+9.85%) [Q4]

3% more funds holding

Funds holding: 29 [Q3] → 30 (+1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 588% upside
• Avg. target: $4 588% upside
• High target: $4 588% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 39% 1-year accuracy 62 / 159 met price target

588% upside $4

Buy Reiterated

29 Jan 2025